




The number of individual cases identified in [EudraVigilance](https://www.adrreports.eu/en/index.html) for COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) is **200,581** (up to 01/05/2021)

SOURCE: EUROPEAN DATABASE OF DRUGS ADVERSE REACTIONS <http://www.adrreports.eu/en/index.html>

TOTAL ADVERSE REACTIONS FOR OXFORD-ASTRAZENECA (up to 01/05/2021)



FATAL REACTIONS REPORTED BY REACTION GROUP (up to 01/05/2021): <https://dap.ema.europa.eu/analytics/saw.dll?PortalPages>

| # | Reaction Groups - Reaction SOC (not linked to ID) | FATAL (Death) | | |
|----|---|---------------------------------|-------------------------|-----------------------|
| 1 | Blood and lymphatic system disorders | 71 | | |
| 2 | Cardiac disorders | 229 | | |
| 3 | Congenital, familial and genetic disorders | 2 | | |
| 4 | Ear and labyrinth disorders | 0 | | |
| 5 | Endocrine disorders | 2 | | |
| 6 | Eye disorders | 6 | | |
| 7 | Gastrointestinal disorders | 80 | | |
| 8 | General disorders and administration site conditions | 542 | | |
| 9 | Hepatobiliary disorders | 15 | | |
| 10 | Immune system disorders | 7 | | |
| 11 | Infections and infestations | 117 | | |
| 12 | Injury, poisoning and procedural complications | 27 | | |
| 13 | Investigations | 28 | | |
| 14 | Metabolism and nutrition disorders | 24 | | |
| 15 | Musculoskeletal and connective tissue disorders | 18 | | |
| 16 | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 4 | | |
| 17 | Nervous system disorders | 289 | | |
| 18 | Pregnancy, puerperium and perinatal conditions | 1 | | |
| 19 | Product issues | 0 | | |
| 20 | Psychiatric disorders | 16 | | |
| 21 | Renal and urinary disorders | 14 | | |
| 22 | Reproductive system and breast disorders | 0 | | |
| 23 | Respiratory, thoracic and mediastinal disorders | 211 | | |
| 24 | Skin and subcutaneous tissue disorders | 13 | | |
| 25 | Social circumstances | 4 | | |
| 26 | Surgical and medical procedures | 14 | | |
| 27 | Vascular disorders | 112 | | |
| | | Total deaths (not linked to ID) | total adverse reactions | ratio death/reactions |
| | TOTAL FATAL REACTIONS (DEATHS) NOT LINKED TO ID | 1,846.00 | 200,581.00 | 0.92% |
| | | Total deaths (linked to ID) | total adverse reactions | ratio death/reactions |
| | TOTAL DEATHS LINKED TO ID | 343.00 | 200,581.00 | 0.17% |